This press release is a routine clinical data presentation with no immediate financial or regulatory catalyst for Teva. Traders should monitor for any future regulatory actions or label expansions related to TD treatments, but no near-term stock-moving event is indicated.
Price Chart
Executive Summary
Teva presented new IMPACT-TD Registry data at the 2026 APA Annual Meeting, revealing that 85% of young adults (18-29) with mood disorders and tardive dyskinesia experience moderate-to-severe impact, yet only 23% received a formal diagnosis. The data highlights a significant diagnostic gap and underscores Teva's commitment to TD research, but the press release contains no financial figures, no regulatory decision, and no change to Teva's commercial outlook.
Key Facts
- New IMPACT-TD Registry data presented at APA 2026 shows 85% of young adults (18-29) with mood disorders and TD experience moderate-to-severe impact.
- Only 23% of young adults (18-29) with TD received a formal diagnosis, revealing a diagnostic gap.
- Average delay in TD diagnosis is more than 3.5 years after involuntary movements are first recognized.
- The IMPACT-TD Registry is a 3-year, prospective, Phase 4 study with 611 participants.
- No financial data, revenue figures, or changes to Teva's product pipeline were disclosed in the press release.
Financial Impact
No financial impact disclosed; the press release is a clinical data update with no revenue or earnings implications.
Risk Factors
- No new commercial or regulatory catalyst; the data does not change Teva's near-term revenue or earnings outlook.
- Diagnostic gap findings may not translate into increased prescribing or market share for Teva's TD treatments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296535 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.29 (+8.09%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.29 (+6.88%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.29 (+4.80%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.29 (+7.82%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.29 (+8.72%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.29 (+12.87%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.29 (+12.23%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.29 (+13.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access